ehc2018 brochure final - biopeople · start clinical trials phase 1 (first-in-human). aptatargets...
TRANSCRIPT
Semifinals2018
European Health Catapult (EHC) is a training programme and competition that boosts the development of top notch European health start-ups in Biotech, Medtech and Digital Health through exposure to leading experts and international investors.The programme is organized by EIT Health with the support of the Health Axis Europe.
The European Health Catapult provides investors/industry representatives an excellent oppor-tunity to gain access to a concentrated elite group of top European start-up companies ready to take on a strong partner when they take the first step to economic value creation. We would like to invite investors/industry representatives to our semifinals, in which the top start-up companies from all over Europe are pitching in front of a hand-picked group of inves-tors/industry representatives after 2 days of intense mentoring and business model optimiza-tion.
Biotech start-ups (semifinal 1): 26 September in Leuven, BelgiumMedtech start-ups (semifinal 2): 3 October in Grenoble, FranceDigital health start-ups (semifinal 3): 10 October in Erlangen, Germany
Contacts:
Biotech Semifinal: Bart Haex ([email protected])Medtech Semifinal: Anais Delicourt ([email protected])Digital Health Semifinal: Marco Wendel ([email protected])
For general interests in Investors opportunities within EIT Health please visit EIT Health Inves-tor Network for more info.
European Health Catapult in cooperation with HEALTH AXIS EUROPEwww.europeanhealthcatapult.eu | www.eithealth.eu | www.health-axis.eu
BioTech
EIT HealthSpain
EIT HealthGermany
MedTech Digital Health
Pitch SessionEIT Health Summit
European HealthCatapult
EIT HealthUK-Ireland
EIT HealthScandinavia
EIT HealthBeNe
EIT HealthFrance
InnoStars
“European Final“, pitching in front ofpartners, stakeholders and investors
“Semifinals“, with pitch training andspecial invitation for investors
European Health Catapult Journey in cooperation with HEALTH AXIS EUROPE
1
European Health Catapult in cooperation with HEALTH AXIS EUROPE
BENEFITS FOR START-UPS
PRIZE MONEY
overall prize money of €135 000In each category – Digital Health, Biotech & Medtech1st place €20.0002nd place €15.0003rd place €10.000
VISIBILITY
360° INDIVIDUALISED TRAINING Optimize your business plan and strengthen your ability to pitch in front of top-level
investors and industry experts
PEER-TO-PEER CONNECTION With leading innovative healthcare start-ups from all over Europe and a rich alumni
program with follow-up networking events
SERVICES
Pitch in front of top level seeds or series A investors of world leading medtech,biotech, pharma and IT companies
Access to the unique EIT Health Accelerator ecosystem and services in crucial areas such as clinical validation (Living Labs and Test Beds) and market preparation for internationalization (GoGlobal)
MedtechADmit Therapeuticswww.admit-therapeutics.com
Aenitiswww.aenitis.fr
Biopromicwww.biopromic.com
GlyCardial Diagnosticswww.glycardial.com
HydrUStentwww.hydrustent.com
Inga Wellbeingwww.ingawellbeing.com
Kirubotics Surgical Solutionswww.kiruboticsurgical.com
Latch Medicalhttp://latch-medical.com
Medical Magnesiumwww.medical-magnesium.com
Neurallyswww.neurallys.com
PlasmaCurewww.plasmacure.nl
Ri.Tewww.ri-te.pt
Sensarswww.sensars.com
Suturion
TADAMedicalhttp://tadamedical.com
VitaDXhttp://vitadx.com/en/
BiotechAptaTargetswww.aptatargets.com
Aquarraywww.aquarray.com
Cambridge Oncometrixwww.camonx.com
Digital Test Tubewww.digitaltesttube.com
FreeOx Biotechwww.freeoxbiotech.com
Gedea Biotechwww.gedeabiotech.com
KYME NANOIMAGING
LIfT BioScienceswww.liftbiosciences.com
Nanoligentwww.nanoligent.com
Pharmgenomicshttps://coloalert.de
Sinntaxiswww.sinntaxis.com
Smart Immune
Synmabtixwww.synmabtix.com
SyNoesis
Digital HealthConsense Data
Dr. Omnibushttps://www.dromnibus.com
FeetMewww.feetme.fr
iBreve
Kinesis Health Technologieswww.kinesis.ie
Mindpaxwww.mindpax.me
Minnitywww.minnity.com
MyBasePairwww.mybasepair.com
NeuroPsyCadwww.neuropsycad.com
Sleepiz
WeFighthttps://www.wefight.co/
Yapilihttp://www.yapili.com
List of nominees per categoryEuropean Health Catapult 2018
Investor NetworkThe EIT Health Investor Network is the first pan-European, EU-driven network solely focused on financing health innovation.It aims at connecting both health-oriented private-equity investors with pre-screened high potential healthcare startups from early to late development stages
Start-ups in Healthcare
If you are a representative of a European Health start-up, seeking seed, Series A, B or C funding, the Investor Network offers you various opportunities to reach out for funding and gain market exper-tise.
Investors in HealthcareIf you are a private investor, business angel association, representative of a VC or corporate venture fund, the Network gives you the opportunity to screen and select young, innovative companies according to the properties of your portfolio and benefit from building new relationships within this close health Investment network.
To find out more contact your regional EIT Health Business Creation Managers or [email protected].
www.eithealth.eu/investors-network2018
Mentoring and Coaching NetworkThe Mentoring and Coaching Network (MCN) connects EIT Health´s individual experts, partners, institutions and corporations, and leverages this robust European know-how with a platform to best support start-ups through individual mentoring. Its core value is to facilitate connections and exchange know-how – helping health and healthcare start-ups get advice from that person who has the expertise needed at that very moment.
BenefitsThe MCN offers start-ups:• Established mentoring programmes, with to-do lists and personalised check-ins to ensure the engagement is successful.• The support of EIT Health's local Business Creation Managers, who guide you through the process.The MCN offers mentors:• An opportunity to mentor the world-class and innovative healthcare start-ups associated with EIT Health.• A chance to be a part of building the European go-to platform of healthcare subject matter experts.
Both start-ups and mentors have the opportunity to reach-out, connect and build success together.
How to apply
Start-ups who are looking for mentoring can apply here. Start-ups are asked to contact your local Business Creation Manager, who is listed on this page, to get started.Industry experts who would you like to join as mentors are asked to apply here.
www.eithealth.eu/accelerator/mentoring-and-coaching-network
Immune modulator for acute treatment of stroke
EIT Health SpainAptaTargets
Company name: AptaTargetsAddress: Av. Cardenal Herrera Oria,298, 28035 Madrid – SpainContact person: David SegarraEmail: [email protected] Phone number: +34 910 568 359Website: www.aptatargets.com
Focused on therapeutic aptamers, AptaTargets is currently developing ApTOLL, an immune modu-lator for acute treatment of Stroke which represents a novel approach to treat stroke in the acute phase and substantially reducing the brain damage. With the Pre-clinical phase already complet-ed, ApTOLL showed outstanding pharmacodynamics with excellent safety profile and is ready to start clinical trials phase 1 (first-in-human). AptaTargets plans to conduct a Phase 2 trial in stroke patients, being this the basic objective of the Series B (€8,5 M, 2019). Additionally, new programs in other indications will be conducted, such as Hemorrhagic Stroke, Myocardial Infarction and Multiple Sclerosis.
Biotech
Novel highly miniaturized biochemical and cell based screenings
EIT Health GermanyAquarray
Company name: Aquarray - spin-off project of KITAddress: Hermann-von-Helmholtz-Platz 1,B 341 R 157, 76344 Eggenstein-Leopoldshafen, GermanyContact person: Dr. Simon WidmaierEmail: [email protected]: www.aquarray.com
Aquarray’s proprietary Droplet Microarray (DMA) is a product innovation which enables novel highly miniaturized biochemical and cell based screenings. The DMA is saving costs by miniaturi-zation while both, accelerating screening and increasing the predictivity of screening results by enabling physiologically more relevant screening models. Aquarray addresses the submarkets Consumables and Reagents with a volume of USD 5.3 billion. Aquarray products meet the grow-ing demand for primary and stem cell screenings addressing three customer segments: funda-mental life sciences, personalized medicine and industrial drug discovery.
Biotech
Focused on therapeutic aptamers, AptaTargets is currently developing ApTOLL, an immune modu-lator for acute treatment of Stroke which represents a novel approach to treat stroke in the acute phase and substantially reducing the brain damage. With the Pre-clinical phase already complet-ed, ApTOLL showed outstanding pharmacodynamics with excellent safety profile and is ready to start clinical trials phase 1 (first-in-human). AptaTargets plans to conduct a Phase 2 trial in stroke patients, being this the basic objective of the Series B (€8,5 M, 2019). Additionally, new programs in other indications will be conducted, such as Hemorrhagic Stroke, Myocardial Infarction and Multiple Sclerosis.
Cost-effective early detection of prostate cancer
EIT Health UK-IrelandCambridge Oncometrix
Company name: Cambridge Oncometrix Ltd.Address: Norwich Research Park,Colney Ln, Norwich, NR4 7GJ, UKContact person: Dr. Maxim Rossmann, CEO Email: [email protected] Number: +44(0) 1603 274 521Website: www.camonx.com
Cambridge Oncometrix develops a highly accurate non-invasive risk stratification test for pros-tate cancer. The test is based a panel of Cambridge Oncometrix proprietary biomarkers and will be offered as a centralized laboratory service for primary and secondary care diagnostic market. The test monitors prostate function and will help to avoid unnecessary prostate biopsies and also identify men who would benefit from expensive and invasive prostate cancer diagnostic proce-dures, such as mpMRI and prostate biopsies. Cambridge Oncometrix test meets global demand expressed by health care the providers and patients for a cost-effective and accurate alternative for the PSA test.
Biotech
The World's First Integrated PCR Software Solution
EIT Health UK-IrelandDigital Test Tube Limited
Company name: Digital Test Tube LimitedAddress: Ballymountain, Ferrybank,Waterford, Ireland - X91 V2CFContact person: Daniel ThewlisEmail: [email protected]: www.digitaltesttube.com
Digital Test Tube (DTT) is the world's first integrated PCR software solution that will change the status quo of the Polymerase Chain Reaction (PCR) testing market. PCR is the principal technique used in DNA analysis for medical, forensic & food safety applications. DTT makes PCR laboratory workflows 20 times more accurate and saves 35-60% of time per experiment, by automating and offering faster throughput on existing laboratory information systems. DTT achieves this through the use of pattern recognition software for the automated labelling & analysis of photographic results. We are looking to raise €1M seed funding to expand our portfolio of users in the food diagnostics and R&D sectors.
Aquarray’s proprietary Droplet Microarray (DMA) is a product innovation which enables novel highly miniaturized biochemical and cell based screenings. The DMA is saving costs by miniaturi-zation while both, accelerating screening and increasing the predictivity of screening results by enabling physiologically more relevant screening models. Aquarray addresses the submarkets Consumables and Reagents with a volume of USD 5.3 billion. Aquarray products meet the grow-ing demand for primary and stem cell screenings addressing three customer segments: funda-mental life sciences, personalized medicine and industrial drug discovery.
Biotech
Oxidative Stress and New Neuroprotective Agents
EIT Health SpainFreeOx Biotech, S.L.
Company name: FreeOx Biotech, S.L.Address: C/ Consell de Cent 373, 2-1. 08009 – Barcelona (Spain)Contact person: Carlos LurigadosEmail: [email protected] number: +34 629 06 12 97Website: http://www.freeoxbiotech.com
Stroke is a leading cause of death and disability worldwide. One in every six people develop a stroke during their lifetime, one third of patients die, and another third experience permanent disability. FreeOx Biotech is a company focused on developing medicines addressed to reduce the effects of the oxidative stress in the organism, especially those related to the neurological and cardiovascular systems. Our lead product, Ox-01, has a proven effect in preventing the damage caused by reperfusion after stroke. A Phase IIb clinical trial successfully conducted in 420 patients indicated that it would be particularly useful in patients undergoing mechanical thrombectomy.
Cambridge Oncometrix develops a highly accurate non-invasive risk stratification test for pros-tate cancer. The test is based a panel of Cambridge Oncometrix proprietary biomarkers and will be offered as a centralized laboratory service for primary and secondary care diagnostic market. The test monitors prostate function and will help to avoid unnecessary prostate biopsies and also identify men who would benefit from expensive and invasive prostate cancer diagnostic proce-dures, such as mpMRI and prostate biopsies. Cambridge Oncometrix test meets global demand expressed by health care the providers and patients for a cost-effective and accurate alternative for the PSA test.
Biotech
An antibiotic-free and safe treatment of vaginal infections
EIT Health ScandinaviaGedea Biotech AB
Company name: Gedea Biotech ABAddress: Medicon Village, Scheelev.2, 223 81 Lund, SwedenContact person: Annette SäfholmEmail: [email protected]: www.gedeabiotech.com
Gedea Biotech develops a safe and antibiotic-free treatment of vaginal infections, affecting most women. It is dually efficient against both pathogenic bacteria and fungi. In addition, it restores normal vaginal pH and removes biofilm, which is important for achieving a long-lasting effect and prevent recurrence. Gedea’s innovative research is paving the way for new therapeutic possibili-ties in the treatment of vaginal infections, while reducing the problem of antimicrobial resistance. The product is to be launched as an OTC medical device in collaboration with a pharmaceutical company in 2019/2020.
Digital Test Tube (DTT) is the world's first integrated PCR software solution that will change the status quo of the Polymerase Chain Reaction (PCR) testing market. PCR is the principal technique used in DNA analysis for medical, forensic & food safety applications. DTT makes PCR laboratory workflows 20 times more accurate and saves 35-60% of time per experiment, by automating and offering faster throughput on existing laboratory information systems. DTT achieves this through the use of pattern recognition software for the automated labelling & analysis of photographic results. We are looking to raise €1M seed funding to expand our portfolio of users in the food diagnostics and R&D sectors.
Biotech
Stroke is a leading cause of death and disability worldwide. One in every six people develop a stroke during their lifetime, one third of patients die, and another third experience permanent disability. FreeOx Biotech is a company focused on developing medicines addressed to reduce the effects of the oxidative stress in the organism, especially those related to the neurological and cardiovascular systems. Our lead product, Ox-01, has a proven effect in preventing the damage caused by reperfusion after stroke. A Phase IIb clinical trial successfully conducted in 420 patients indicated that it would be particularly useful in patients undergoing mechanical thrombectomy.
Prophetic Nanoimaging for Well-Being
InnoStarsKYME NANOIMAGING S.R.L.
Company name: KYME NANOIMAGING S.R.L. Contact person: Enza Torino, PhDEmail: [email protected] Phone Number: +32 89558158
KYME NANOIMAGING produces injectable medical products for Magnetic Resonance Imaging by combining biomaterials with clinically used Contrast Agents (Cas) through a patented nanotech-nology platform based on the Microfluidics, which allows a scalable, controllable and continuous production at low cost.KYME formulation guarantees unique properties: the enhancement of the performances of Cas up to 12 times and the improvement of safety for patients. The products aim to make visible ana-tomical details otherwise not appreciable consequently, ensuring better diagnosis, reducing side effects and widening the range of treatable patients.
Biotech
Gedea Biotech develops a safe and antibiotic-free treatment of vaginal infections, affecting most women. It is dually efficient against both pathogenic bacteria and fungi. In addition, it restores normal vaginal pH and removes biofilm, which is important for achieving a long-lasting effect and prevent recurrence. Gedea’s innovative research is paving the way for new therapeutic possibili-ties in the treatment of vaginal infections, while reducing the problem of antimicrobial resistance. The product is to be launched as an OTC medical device in collaboration with a pharmaceutical company in 2019/2020.
The world’s first cell bank of ‘cancer killing neutrophils’
EIT Health UK-IrelandLIfT BioSciences Ltd
Company name: LIfT BioSciences LtdAddress: 81 Palace Gardens Terrace,Notting Hill Gate, London W8 4AT, UKContact person: Alex BlythEmail: [email protected]: https://www.liftbiosciences.com
LIfT Biosciences Ltd is a Immuno-Oncology Cell Therapy Biotech start-up bringing a 1st in class ATMP to market. Our vision is to develop the world’s first cell bank of ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for all solid tumours. LIfT has already shown 40-80% solid tumour necrosis in an FDA approved small study.LIfT BioSciences stunned the world as they produced N-LIfT: ‘The World’s First Ever Neutrophils Ex-vivo from stem cells to Demonstrate Super Cancer Killing Ability’, and was given first-in-class status by the EMA as an ATMP. N-LIfT is a potentially patented, scalable product that destroys tumours that other therapies can not.
Biotech
Self-assembling protein nanoparticle that selectively kills metastatic cells--
EIT Health SpainNanoligent S.L.
Company name: Nanoligent S.L.Address: Av. de Can Doménech s/n, Campus de la UAB08193 Bellaterra (Cerdanyola del Vallés), Barcelona, SpainContact person: Manuel RodriguezEmail: [email protected]: http://www.nanoligent.com
Nanoligent is a spin-off of the Universitat Autónoma de Barcelona and Hospital de Sant Pau. Our product is a nanoconjugate that selectively targets the CXCR4 receptor which is present in meta-static cells of at least 23 types of cancers. It obtained very successful results in preclinical studies reducing metastasis in colorectal cancer and acute myeloid leukemia. We are now working to select the best candidate for development. After this, we will conduct preclinical tests in order to get approval to start phase I clinical trial. We plan to complete phase I clinical trial and then reach a licensing agreement with a pharma company to continue the devel-opment.
KYME NANOIMAGING produces injectable medical products for Magnetic Resonance Imaging by combining biomaterials with clinically used Contrast Agents (Cas) through a patented nanotech-nology platform based on the Microfluidics, which allows a scalable, controllable and continuous production at low cost.KYME formulation guarantees unique properties: the enhancement of the performances of Cas up to 12 times and the improvement of safety for patients. The products aim to make visible ana-tomical details otherwise not appreciable consequently, ensuring better diagnosis, reducing side effects and widening the range of treatable patients.
Biotech
LIfT Biosciences Ltd is a Immuno-Oncology Cell Therapy Biotech start-up bringing a 1st in class ATMP to market. Our vision is to develop the world’s first cell bank of ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for all solid tumours. LIfT has already shown 40-80% solid tumour necrosis in an FDA approved small study.LIfT BioSciences stunned the world as they produced N-LIfT: ‘The World’s First Ever Neutrophils Ex-vivo from stem cells to Demonstrate Super Cancer Killing Ability’, and was given first-in-class status by the EMA as an ATMP. N-LIfT is a potentially patented, scalable product that destroys tumours that other therapies can not.
CRC screening test ColoAlert --
EIT Health GermanyPharmgenomics GmbH
Company name: Pharmgenomics GmbHAddress: Robert-Koch-Str. 50, 55129 Mainz, GermanyContact person: Philipp FreeseEmail: [email protected]: https://coloalert.de
ColoAlert is the World’s first affordable stool-based tumor DNA colorectal cancer (CRC) screening test. It combines the occult blood detection with 3 genetic biomarkers strongly connected to CRC tumorigenesis, showing a leading 85 % sensitivity in an independent case cohort study while meeting the recommended 90 % specificity threshold.
The target group consists of 160 M people aged 50+ not undergoing colonoscopy in the EU alone, leading to yearly revenues in the 9 digit area with a modest 3 % market share. A comparable posi-tion made ColoAlert’s lonely competitor, Exact Sciences Corp, hit a market evaluation of over $ 7 B though being no option for the EU market due to its $ 500 price tag.
Biotech
Developing the first medical therapy restoring functional abilities after stroke
EIT Health ScandinaviaSinntaxis AB
Company name: Sinntaxis ABAddress: SmiLe incubator, Medicon Village,Scheelevägen 2, 223 81 Lund, SwedenContact person: Michael Oredsson, CEO Email: [email protected] number: +46 707188930Website: https://www.sinntaxis.com
Stroke affects about 17M individuals annually but no drug therapy exists.Less than 15% of stroke patients get thrombolysis but all could be treated with a recovery-en-hancing drug. Many stroke survivors suffer lifelong disability, costing society about 100,000 US$ per year.Sinntaxis has patented and validated mGluR5 NAMs preclinically in stroke recovery, a class of molecules with ample safety data from trials in other brain conditions, and will start a PII stroke recovery trial in 2019. Sinntaxis management has vast experience in CNS R&D and BD and has an established global network of Key Opinion Leaders.
Nanoligent is a spin-off of the Universitat Autónoma de Barcelona and Hospital de Sant Pau. Our product is a nanoconjugate that selectively targets the CXCR4 receptor which is present in meta-static cells of at least 23 types of cancers. It obtained very successful results in preclinical studies reducing metastasis in colorectal cancer and acute myeloid leukemia. We are now working to select the best candidate for development. After this, we will conduct preclinical tests in order to get approval to start phase I clinical trial. We plan to complete phase I clinical trial and then reach a licensing agreement with a pharma company to continue the devel-opment.
Biotech
Smart immune – A platform to regenerate your immune system
EIT Health FranceSmart Immune
Company name: Smart ImmuneAddress: Faculté de Médecine Paris Descartes,24 rue du Faubourg St Jaques, 75014 ParisContact person: Julien EtterspergerEmail: [email protected] Phone Number: +33 6 59 12 18 87
Smart Immune is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat T-cell immunodeficiencies such as SCID (“bubble boy”) or patients with chemotherapy. The patented Smart Immune technology accelerates T-cell differentiation through an ex vivo artificial thymus, reducing post-transplantation immunodeficiency period from +12 months to 1-2 months. Developed by two world-renowned KOL, Dr André-Schmutz and Pr Cavazzana, Smart Immune will change the prognosis of patients, allowing bone marrow transplantation to a larger number of patients without adverse reactions. Our first clinical trial is funded with French government grant, IND has been sent to ANSM and our first patient should be enrolled by end 2018.
Biotech
Stroke affects about 17M individuals annually but no drug therapy exists.Less than 15% of stroke patients get thrombolysis but all could be treated with a recovery-en-hancing drug. Many stroke survivors suffer lifelong disability, costing society about 100,000 US$ per year.Sinntaxis has patented and validated mGluR5 NAMs preclinically in stroke recovery, a class of molecules with ample safety data from trials in other brain conditions, and will start a PII stroke recovery trial in 2019. Sinntaxis management has vast experience in CNS R&D and BD and has an established global network of Key Opinion Leaders.
Developing immune modulating therapeutic antibody leads --
EIT Health BeNeSynmabtix
Company name: Synmabtix BVAddress: Oxfordlaan 70, 6229EV Maastricht, The NetherlandsContact person: Yvo Graus, PhD, MBAEmail: [email protected]: +31 (0)651773294Website: www.synmabtix.com
Synmabtix develops antibody-based drugs for the treatment of chronic inflammatory diseases, based on knowledge of the innate immune system. Synmabtix develops antibody leads that acti-vate the brake on ongoing inflammatory processes, central in chronic inflammatory diseases.Synmabtix business model is focused on developing multiple antibody leads up to clinical proof of concept (Phase II clinical trials) after which the product will be partnered with Big Pharma. Anti-body based drugs are broadly used in the treatment of cancer and inflammatory conditions and provide huge value potential. Synmabtix is a joint venture of Radboud University Medical Center & Maastricht University.
Biotech
Smart Immune is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat T-cell immunodeficiencies such as SCID (“bubble boy”) or patients with chemotherapy. The patented Smart Immune technology accelerates T-cell differentiation through an ex vivo artificial thymus, reducing post-transplantation immunodeficiency period from +12 months to 1-2 months. Developed by two world-renowned KOL, Dr André-Schmutz and Pr Cavazzana, Smart Immune will change the prognosis of patients, allowing bone marrow transplantation to a larger number of patients without adverse reactions. Our first clinical trial is funded with French government grant, IND has been sent to ANSM and our first patient should be enrolled by end 2018.
A novel multi-acting drug to cure Parkinson's disease and other major brain diseases
InnoStarsSyNoesis Therapeutics Ltd.
Company name: SyNoesis Therapeutics Ltd.Address: Strobόlou 47, KYROS TOWER,Floor 5, 2018, Nicosia, CyprusContact person: Thanasis SpathisEmail: [email protected] Number: +306944281339
SyNoesis Therapeutics is a start-up biotech with the vision to cure Parkinson's disease (PD) and other major brain diseases. We aim to capitalize on the potential of a new therapeutic we have patented for PD to be further developed towards being successful in clinical trials and become the first drug to cure it.The therapeutic covers remarkably the major unmet needs of PD in several mouse models and has drug-like properties. We filed a PCT application and we are expressed funding interest by big pharmas. Importantly, we have shown that the therapeutic efficacy of our compound also applies to other major brain diseases. We are currently filing 2 new PCT applications.We seek partners onboard.
Biotech
IVD test for early Alzheimer’s disease (AD) detection,based on blood epigenetic biomarkers
-
EIT Health SpainADmit Therapeutics, S.L
Company name: ADmit Therapeutics, S.LAddress: Carrer Ferran Muñoz, 5-9, 08859 Begues, SpainContact person: Marta BarrachinaEmail: [email protected] number: + 34 93 260 72 15Website: www.admit-therapeutics.com
ADmit Therapeutics is a spin-off from Bellvitge Biomedical Research Institute, and focused on the development of a novel Alzheimer’s disease (AD) early detection tect. AD is an unmet medical need. The pathology is characterized by a long asymptomatic period that has severely interfered with clinical trials, because patients recruited has been performed at advance stages of the disease. We are developing a blood epigenetic test to identify patients at early stages, which will be useful for optimizing patients’ recruitment in clinical trials increasing the probability of new drugs registration. A series A of 1.5M € is needed to start with clinical validation, obtaining CE mark in 2022.
Medtech
EIT Health FranceAenitis Technologies
Continuous, contactless and pressureless sorting of cells in suspensions
Company name: Aenitis TechnologiesAddress: 16 rue de la Grange aux Belles,Batiment Jean Bernard, 75010 Paris - FranceContact person: Emmanuel VincentEmail: [email protected]: www.aenitis.fr
Cost effective and efficient Bioprocessing solutions are main issues in cell therapy. Aenitis devel-op innovative patented medical devices for continuous, contactless and pressurless sorting of cells in suspensions, using Acoustic Radiation Forces. With large added values, Aenitis answer in cell therapy units and blood banks' challenges on cell sorting, on cell washing and on cell isolation for blood, tissues and stem cells processing. Its 1st CE marked devices should be on the market by early 2021.Supported by major companies and largely awarded in Europe, Aenitis received over €5,8M grants and €2M VC funding. In order to close a €3,2M series A funding, Aenitis is still looking for €1,2M.
SyNoesis Therapeutics is a start-up biotech with the vision to cure Parkinson's disease (PD) and other major brain diseases. We aim to capitalize on the potential of a new therapeutic we have patented for PD to be further developed towards being successful in clinical trials and become the first drug to cure it.The therapeutic covers remarkably the major unmet needs of PD in several mouse models and has drug-like properties. We filed a PCT application and we are expressed funding interest by big pharmas. Importantly, we have shown that the therapeutic efficacy of our compound also applies to other major brain diseases. We are currently filing 2 new PCT applications.We seek partners onboard.
Medtech
Biopromic is working to change the future of rapid, point-of-care diagnosticsfor the detection of infectious diseases.
EIT Health ScandinaviaBiopromic AB
Company name: Biopromic ABAddress: Tomtebodavagen 23a, Gamma 6,17165 Solna, Sweden Contact person: Lech Ignatowicz, PhDEmail: [email protected] Website: www.biopromic.com
By combining three of Biopromic’s proprietary technologies we improved sensitivity of lateral flow diagnostic assay over 50x. This resulted in the development of a new spectrum of simple to use, “pregnancy test style”, affordable tests for clinical and veterinary settings. Our aim is to move the infection disease diagnostics from the specialized central lab to GP’s office, patient’s bedside or into farmers hands.
Medtech
GlyCardial Diagnostics: Act before it’s too late
EIT Health SpainGlycardial Diagnostics S.L.
Company name: Glycardial Diagnostics S.L.Address: c/Sant Antoni Maria Claret, 167,Building No. 11, 08025 Barcelona, SpainContact person: Judit Cubedo Ràfols, PhDEmail: [email protected] Phone number: +34 93 5565885Website: www.glycardial.com
GlyCardial Diagnostics is a Barcelona-based spin-off company of the Sant Pau Hospital Research Institute and CSIC (Spanish National Research Council) focused on the development of a novel in vitro diagnostic (IVD) test for the detection of ApoJ-Glyc blood levels for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution. Acute ischemic events are the most common cardiac emergencies with substantial morbidity and mortality worldwide. However, there are no available biomarkers for the early diagnosis of ischemia which is essential to prevent irreversible myocardial damage. Our goal is to bring to a market-ready stage the first IVD for the early detection of ischemia.
Medtech
HydrUStent - Non-degradable is so 20th Century
--
InnoStarsHydrUStent, LDA
Company name: HydrUStent, LDAAddress: Avepark - Parque de Ciência e TecnologiaZona Industrial da Gandra,4805-017 Barco - Guimarães, PortugalContact person: Alexandre BarrosEmail: [email protected] number: +351 253 510 900Website: https://www.hydrustent.com
Every year around 10 million people worldwide need a urological STENT. But did you know that almost 100% of these people develop a bacterial infection within 30 days of implantation? And also, require a second surgery for stent removal? Imagine that we have a product that avoids this. HYDRUSTENT does that!HydrUStent is a biodegradable, anti-bacterial and tailor-made stent which underlying technology has been protecting by a patent. HydrUStent not only reduces the risk of bacterial infection but it also cuts down half the number of surgical procedures reducing the treatment cost by 60%.HydrUStent is a Portuguese spin-off company from 3Bs Research Group, University of Minho a leading group in Biomaterials research. The biodegradable ureteral stent is our first product from a patented biodegradable drug-eluting medical devices pipeline.
Medtech
Comfortable, dignified clothing to empower patients and promote a faster recovery-
-
EIT Health BeNeINGA Wellbeing
Company name: INGA WellbeingAddress: Zonienboslaan 15, 3090 Overijse, BelgiumContact person: Nikla LancksweertEmail: [email protected] Phone number: +32 485 478 818Website: www.ingawellbeing.com
To counter the debilitating impact of the hospital gown, INGA Wellbeing worked with nurses to create award-winning day- and nightwear that accommodates with IV lines, drains and moni-tors. Able to dress themselves, patients feel in control and are more likely to walk and enjoy visitors and thus improve their wellbeing and recovery. Medical staff are able to access the body quickly and easily for routine examinations and treatments, saving valuable time, and providing the kind of respectful care that ensures a good patient experience. Sales have begun online and we are working with a prominent Belgian hospital to develop an institutional version that can loaned to patients during their hospital stay. In this way, we hope to make our clothing solutions more widely available and to encourage sales of the consumer range.
Medtech
Universalizing Robotic Surgery: Laparoscopic Robotic Surgical System for Minimal Invasive Surgery (MIS) for Pelvic and Abdominal procedures
EIT Health SpainKirubotics Surgical Solutions
Company name: Kirubotics Surgical SolutionsAddress: Calle del Brezo 6, 14012 Córdoba, SpainContact person: Fernando Mateo AriasEmail: [email protected]: www.kiruboticsurgical.com
The goal of KIRUBOTICS is to enter in the strategic sector of Robotic Laparoscopic Surgery, a rela-tively nascent sector with high annual growth expectations. KIRUBOTICS aims to contribute with high add value solutions to improve current benefits of Surgical Robotics and solve those prob-lems that obstruct the massive using of Robotics Surgery in Health Sector: high investment cost, high cost of spares parts and high maintenance cost.KIRUBOTICS starts its activity based on a precommercial prototype tested with dummies and developed collaboratively by Surgeons. We already are immersed in industrialization and certifi-cation phase of our Robot for Pelvic and Abdominal procedures with an estimation of first sales in 2021.
Every year around 10 million people worldwide need a urological STENT. But did you know that almost 100% of these people develop a bacterial infection within 30 days of implantation? And also, require a second surgery for stent removal? Imagine that we have a product that avoids this. HYDRUSTENT does that!HydrUStent is a biodegradable, anti-bacterial and tailor-made stent which underlying technology has been protecting by a patent. HydrUStent not only reduces the risk of bacterial infection but it also cuts down half the number of surgical procedures reducing the treatment cost by 60%.HydrUStent is a Portuguese spin-off company from 3Bs Research Group, University of Minho a leading group in Biomaterials research. The biodegradable ureteral stent is our first product from a patented biodegradable drug-eluting medical devices pipeline.
Medtech
Rapid, robust, reliable and readily reversible catheter securement
--
EIT Health UK-IrelandLatch Medical
Company name: Latch MedicalAddress: Belfield Innovation Park,University College Dublin, Belfield, Dublin 4 Contact person: Nicky Bertollo, Ph.D.Email: [email protected]: http://latch-medical.com/
Catheter-Related Blood Stream Infections are a leading cause of preventable treatment-related mortality, killing up to 20k US patients/yr. Current central catheter stabilisation solutions help mitigate this risk, but adhesive devices, the mainstay of treatment, require constant replacement, cause skin injuries and impairment which increases clinical complexity and costs. Latch Medical have developed the CathLatch, based on revolutionary microarray technology which achieves rapid, robust, reliable and readily reversible catheter securement through painless sub-millimetre microarray anchorage into the outer layers of skin. Our highly cost-effective, clinically superior approach puts patients first.
Medtech
Medical Magnesium develops the next generation of implants.
EIT Health GermanyMedical Magnesium GmbH
Company name: Medical Magnesium GmbHAddress: Philipsstraße 8, 52068 Aachen, Germany Contact person: Florian Coppers, CEOEmail: [email protected] number: +49 176 12677 377Website: www.medical-magnesium.com
The goal of KIRUBOTICS is to enter in the strategic sector of Robotic Laparoscopic Surgery, a rela-tively nascent sector with high annual growth expectations. KIRUBOTICS aims to contribute with high add value solutions to improve current benefits of Surgical Robotics and solve those prob-lems that obstruct the massive using of Robotics Surgery in Health Sector: high investment cost, high cost of spares parts and high maintenance cost.KIRUBOTICS starts its activity based on a precommercial prototype tested with dummies and developed collaboratively by Surgeons. We already are immersed in industrialization and certifi-cation phase of our Robot for Pelvic and Abdominal procedures with an estimation of first sales in 2021.
Medical Magnesium is a medtech start-up that revolutionizes modern patient care by developing and marketing bioabsorbable orthopedic implants made of magnesium. The current standard of care to cure bone fractures requires a removal surgery of the permanent implant material. Patients inevitably suffer from unnecessary pain, longer healing time, high risk of infection caus-ing increased healthcare costs. Medical Magnesium has developed a new class of bioabsorbable implants that eliminate the need for a removal surgery, as they absorb in a controlled manner after healing the fracture. Together with leading users from orthopedics and trauma surgery the team strives for a better patient care.
Medtech
Providing a new life to patients with hydrocephalus
EIT Health FranceNEURALLYS
Company name: NEURALLYSAddress: Institut du Cerveau et de la moëlle épinièreHôpital de la Pitié Salpétrière –iPEPS,47/83 Boulevard de l’hôpital,75013 PARIS, FranceContact person: Philippe AuvrayEmail: [email protected]: www.neurallys.com
The hydrocephalus concerns more than 800,000 patients in Europe and in the US. The pathology is either congenital or induced after head traumas, strokes, brain tumors, causing high intracranial pressure. The patients are treated with an implanted shunt (regulating the intracranial pressure) but having high failure rates. The patients need frequent visits to hospital emergency department and the requirement for exploratory surgeries. Neurallys is developing a connected medical device to improve the patient’s comfort of live and to bring the neurosurgeons, a new tool for better patient follow-up and more accurate shunt failure diagnosis.
Catheter-Related Blood Stream Infections are a leading cause of preventable treatment-related mortality, killing up to 20k US patients/yr. Current central catheter stabilisation solutions help mitigate this risk, but adhesive devices, the mainstay of treatment, require constant replacement, cause skin injuries and impairment which increases clinical complexity and costs. Latch Medical have developed the CathLatch, based on revolutionary microarray technology which achieves rapid, robust, reliable and readily reversible catheter securement through painless sub-millimetre microarray anchorage into the outer layers of skin. Our highly cost-effective, clinically superior approach puts patients first.
Medtech
EIT Health BeNe Plasmacure B.V.
Healing chronic wounds and preventing from amputation
Company name: Plasmacure B.V.Address: High Tech Campus 12,5656 AE Eindhoven, The NetherlandsContact person: Bas ZeperEmail: [email protected] Phone number: +31 6 52736130Website: http://www.plasmacure.nl/
Around 10 million patients in Europe develop diabetic foot, venous leg and pressure ulcers. For 3% of diabetic foot patients these wounds result in an amputation. This decreases quality of life for patients. Our goal is to prevent this and heal wounds with Plasoma.Plasoma is a chronic wound healing device consisting of an electronic pad that creates a cold plasma in the wound and a pulser that sends the electric current to the pad. When applied to the wound the cold plasma kills the bacteria and stimulates healing. This quick and painless treat-ment decreases the risk for amputation and contributes to a patient’s quality of life.
Medical Magnesium is a medtech start-up that revolutionizes modern patient care by developing and marketing bioabsorbable orthopedic implants made of magnesium. The current standard of care to cure bone fractures requires a removal surgery of the permanent implant material. Patients inevitably suffer from unnecessary pain, longer healing time, high risk of infection caus-ing increased healthcare costs. Medical Magnesium has developed a new class of bioabsorbable implants that eliminate the need for a removal surgery, as they absorb in a controlled manner after healing the fracture. Together with leading users from orthopedics and trauma surgery the team strives for a better patient care.
Medtech
Cost-effective PET scanners for training and medical research
EIT Health InnoStarsRI-TE Radiation Imaging Technologies
Company name: RI-TE Radiation Imaging TechnologiesAddress: UA Incubator, PCI Creative Science Park, 830-352 Ílhavo, PortugalContact person: Filipe CastroEmail: [email protected]: +351 93 665 7175Website: www.ri-te.pt
RI-TE is a spin-off company from the University of Aveiro specialized in cost-effective PET scan-ners for education, training and preclinical research. Thanks to a proprietary intelligent scanning method, RI-TE scanners achieve great performance while reducing complexity and costs by more than 80%, thus enabling a much wider use of this powerful but costly technology. RI-TE is devel-oping two systems of growing complexity, for different segments:1) easyPET – a unique PET scanner for education & training (Universities and Health Schools) – ready to market;2) iPET – the preclinical PET scanner with the best cost-performance (for small animal imaging research centers, CROs, pharma industry) – under development.
Medtech
Restoring limb functionalities to people affected byextremities amputation or nerve damages
-
EIT Health GermanySensArs Neuroprosthetics
Company name: SensArs NeuroprostheticsAddress: c/o Francesco Petrini,Av. De Sévelin 13b 1004 Lausanne, SwitzerlandContact person: Francesco Petrini, PhDEmail: [email protected], Phone number: +393494481973Website: http://www.sensars.com
Medical Magnesium is a medtech start-up that revolutionizes modern patient care by developing and marketing bioabsorbable orthopedic implants made of magnesium. The current standard of care to cure bone fractures requires a removal surgery of the permanent implant material. Patients inevitably suffer from unnecessary pain, longer healing time, high risk of infection caus-ing increased healthcare costs. Medical Magnesium has developed a new class of bioabsorbable implants that eliminate the need for a removal surgery, as they absorb in a controlled manner after healing the fracture. Together with leading users from orthopedics and trauma surgery the team strives for a better patient care.
Medtech
The Suturion project is developing and evaluating a sewing machine for long surgical suture lines
EIT Health ScandinaviaSUTURION AB
Company name: SUTURION ABAddress: Lindforsgatan 4, 256 54 Ramlösa, SwedenContact person: Gabriel BörnerEmail: [email protected]
The innovation facilitates for the surgeon to adhere to best practice principles of abdominal closure wich is essential to lower the risk for incisional hernia. The innovation also reduces abdominal closure time to 1/4 and minimizes the risk for prick injuries. To build value we filed patent application, performed market analysis and pre-clinical research and plan to do a regulato-ry investigation and CE-marking. The pre-clinical research provided proof of concept and we plan to start a randomized clinical study on colorectal patients in 2019. Further fundings will be needed to adapt the innovation to mass production and to run the clinical study.
S U T U R O N
RI-TE is a spin-off company from the University of Aveiro specialized in cost-effective PET scan-ners for education, training and preclinical research. Thanks to a proprietary intelligent scanning method, RI-TE scanners achieve great performance while reducing complexity and costs by more than 80%, thus enabling a much wider use of this powerful but costly technology. RI-TE is devel-oping two systems of growing complexity, for different segments:1) easyPET – a unique PET scanner for education & training (Universities and Health Schools) – ready to market;2) iPET – the preclinical PET scanner with the best cost-performance (for small animal imaging research centers, CROs, pharma industry) – under development.
Medtech
No more patient injuries caused by dislodged medical tubes
EIT Health ScandinaviaTADA Medical
Company name: TADA MedicalAddress: Drottninggatan 102, 11 60 Stockholm, SwedenContact person: Katarina Hedbeck, CEOEmail: [email protected] Website: http://tadamedical.com
Global statistics show that 10% of medical tubes are accidentally pulled and damaged, resulting in loss of medicine, patient injury and possibly death.TADA Medical has invented a fail-safe connector made to keep the tube, patient and personnel safe. Our connector is cheap and mass producible, perfect for protecting the 3.5 billion tubes currently at risk of being pulled. The market is estimated to 7 billion euros a year.We have a highly competent team of doctors and engineers, and a patented technology with the potential to set a new EU-standard for tube protection and take the global fight for patient safety to the next level.Will you join our quest? Join TADA!
Medical Magnesium is a medtech start-up that revolutionizes modern patient care by developing and marketing bioabsorbable orthopedic implants made of magnesium. The current standard of care to cure bone fractures requires a removal surgery of the permanent implant material. Patients inevitably suffer from unnecessary pain, longer healing time, high risk of infection caus-ing increased healthcare costs. Medical Magnesium has developed a new class of bioabsorbable implants that eliminate the need for a removal surgery, as they absorb in a controlled manner after healing the fracture. Together with leading users from orthopedics and trauma surgery the team strives for a better patient care.
Medtech
EIT Health FranceVitaDX International
Innovative medical device for early bladder cancer diagnosis
Company name: VitaDX InternationalAddress: 65 Avenue Aristide Briand, 35000 Rennes, FranceContact person: Allan RodriguezEmail: [email protected]: http://vitadx.com/en/
VitaDX combines fluorescence imaging and image processing using machine learning algorithms to detect cancerous cells in a urine sample. The company was created in 2015 and our 12 people are based in Rennes and Paris. We are strongly supported since the beginning of the company by the regions Ile-de-France and Bretagne, BPI, the SATT Paris-Saclay. Our clinical trial on 1400 patients will end in early 2019 and the first solution, VisioCyt, will be commercialized in early 2020. We have fundraised 2.6 M€ in two turns of financing with business angels and Venture Capitalists and are looking for 3 M€ in early 2019.
Medtech
One-stop-shop for informed consent in medical research
EIT Health BeNeConsense Data Exchange BV
Company name: Consense Data Exchange BVAddress: Ravelijsntraat 137 6217 LX Maastricht NetherlandsContact person: Marta Giralt Email: [email protected]: +31687136506Website: https://www.linkedin.com/company/consense-data-exchange/
At Consense we understand the importance of data privacy and good data practices in scientific research. Therefore we are building a platform where individuals express their preferences for data sharing and are matched to the right researchers. Individuals and are then streamlined into a personalized informed consent collection process which stores an immutable integrity proof of participant’s understanding. The benefit for participants is less hassle and more control. The ben-efit for researchers is lower cost and improved auditability of consent forms in case of an inspec-tion from regulatory bodies.
Digital Health
AI-based digital therapeutics for developmental and neurocognitive disorders
EIT Health InnoStarsDr. Omnibus
Company name: DrOmnibus Sp. z o. o.Address: Ul. Dolnych Mlynow 3/1, 31-124 Cracow, Poland Contact person: Michał RyśEmail: [email protected] Number: +1 415 800 4304Website: https://www.dromnibus.com
DrOmnibus deals with the creation of modern digital tools that can be used in developmental and neurocognitive disorders, like Autism or Alzheimer. DrOmnibus solution for Autism has scientifi-cally proven effectiveness.Company next steps are the implementation of AI models based on collected data, clinical trials and obtaining the FDA approvel for its first solution for therapy of Autism, as well as further com-mercialization on the US market and entering therapy markets of other disorders.DrOmnibus is preparing for the Series A ($12M USD) by the end of 2019, however company is already inviting selected investors to participate in this round in the form of convertible notes at a 20% discount.
Digital Health
At Consense we understand the importance of data privacy and good data practices in scientific research. Therefore we are building a platform where individuals express their preferences for data sharing and are matched to the right researchers. Individuals and are then streamlined into a personalized informed consent collection process which stores an immutable integrity proof of participant’s understanding. The benefit for participants is less hassle and more control. The ben-efit for researchers is lower cost and improved auditability of consent forms in case of an inspec-tion from regulatory bodies.
Improve Mobility Outcomes and Home RehabilitationThrough Smart Active Wearable Technology
EIT Health FranceFeetMe
Company name: FeetMeAddress: 157, bd MacDonald – 75019 Paris, France Contact person: Alexis MathieuEmail: [email protected]: www.feetme.fr
Loss of mobility is a growing unmet medical need, 100 million people are suffering from mobility disorders worldwide. FeetMe has a mission to simplify and accelerate therapeutic and rehabilita-tion evaluations through continuous real life mobility assessment. FeetMe Monitor is a connect-ed insole and an associated mobile software that collects and analyze gait spatio-temporal parameters and variability in real life thanks to embedded smart algorithms and wireless connec-tion. Our solution is sold to pharma companies for clinical trials, or to hospital and rehabilitation centers for mobility assessment and gait training and to patients for home rehabilitation.
Digital Health
DrOmnibus deals with the creation of modern digital tools that can be used in developmental and neurocognitive disorders, like Autism or Alzheimer. DrOmnibus solution for Autism has scientifi-cally proven effectiveness.Company next steps are the implementation of AI models based on collected data, clinical trials and obtaining the FDA approvel for its first solution for therapy of Autism, as well as further com-mercialization on the US market and entering therapy markets of other disorders.DrOmnibus is preparing for the Series A ($12M USD) by the end of 2019, however company is already inviting selected investors to participate in this round in the form of convertible notes at a 20% discount.
The wearable that helps people with stress, anxiety and chronic espiratory diseases by analyzing breathing patterns
EIT Health UK-IrelandiBreve
Company name: iBreve LtdAddress: Clifton House Business Centre,Fitzwilliam Street Lower, Dublin 2, IrelandContact person: Flavia WahlEmail: [email protected] Number: +353 899 832 484
Founded by 2 former Google employees iBreve’s vision is to create a world free of stress related diseases.Chronic stress is linked to heart disease as well as mental health disorders. iBreve’s digital health solution is able to prevent stress in an early phase by correlating breathing patterns, activity & stress level in real time. With the help of machine learning iBreve suggests personalized treatment with clinically proven relaxation exercises.iBreve won several innovation challenges, received funding for its dedication to sustainability & got featured in large newspapers around the world.
Digital Health
Loss of mobility is a growing unmet medical need, 100 million people are suffering from mobility disorders worldwide. FeetMe has a mission to simplify and accelerate therapeutic and rehabilita-tion evaluations through continuous real life mobility assessment. FeetMe Monitor is a connect-ed insole and an associated mobile software that collects and analyze gait spatio-temporal parameters and variability in real life thanks to embedded smart algorithms and wireless connec-tion. Our solution is sold to pharma companies for clinical trials, or to hospital and rehabilitation centers for mobility assessment and gait training and to patients for home rehabilitation.
Proven tools for falls risk assessment
EIT Health UK-Ireland Kinesis Health Technologies
Company name: Kinesis Health Technologies Ltd.Address: NexusUCD, Belfield Office Park,Clonskeagh, Dublin D04 V2N9, IrelandContact person: Seamus Small, CEOEmail: [email protected]: www.kinesis.ie
Kinesis Health Technologies are an award winning falls prevention company, a leader in digital health. Falls are a major global healthcare challenge, 30% of adults over 65 years of age fall each year, with 1 in 5 dying within 12 months and 1 in 3 never returning home after a fall related hip fracture. We strongly believe in the power of prevention and are dedicated to engaging and empowering older adults to reduce falls in order to live longer, healthier and independent lives. Kinesis has developed proprietary technologies that are used to Screen, Assess and Intervene and work with health and social care teams around the world to prevent falls among older adults.
Digital Health
Founded by 2 former Google employees iBreve’s vision is to create a world free of stress related diseases.Chronic stress is linked to heart disease as well as mental health disorders. iBreve’s digital health solution is able to prevent stress in an early phase by correlating breathing patterns, activity & stress level in real time. With the help of machine learning iBreve suggests personalized treatment with clinically proven relaxation exercises.iBreve won several innovation challenges, received funding for its dedication to sustainability & got featured in large newspapers around the world.
Mindpax is the new digital medicine company in the psychiatric fielddeveloping a monitoring system to predict severe mental health attacks
EIT Health GermanyMindpax
Company name: MindpaxAddress: Äußere Nürnberger Straße 62, 91301 ForchheimContact person: Pavel Nevicky, CEOEmail: [email protected]: +420 733 786 044Website: www.mindpax.me
First positive results could be shown in a trial, screening schizophrenia patients. This basic system is currently integrated in clinical use in CZ. The underlying algorithm of this monitoring tool is the basis of the development of new digital markers for schizophrenia and bipolar affective disorders. The marker will be generated of a longtime monitoring of sleep additionally to physical activity, measured by a sensor, and a questionnaire chronicling behavioral patterns. To identify clinically validated markers for schizophrenia and bipolar disorder Mindpax is preparing two clinical studies (CITADEL200 and BIPO50DE). In the next 3 years, Mindpax will need 3 Mio. Euro to finance the clinical studies for the identification and validation of the two new digital markers in addition to the CE-mark certification.
Digital Health
The keys to the person in dementia care. At your fingertips.
EIT Health Scandinavia Minnity
Company name: Minnity ABAddress: Drakflygargatan 5, 128 36 Skarpnäck, SwedenContact person: Katarzyna Hess-WiktorEmail: [email protected]: +46 73 890 71 72Website: www.minnity.com
The Minnity app enables professional caregivers to deliver individualized care to every caretaker with the help of a smartphone, thus facilitating faster care and improving its continuity. By provid-ing essential information on the individual's life story and needs in an easily accessible manner, the tool facilitates communication and effective care. It also allows caregivers to improve their skills through supplying them with micro-learning solutions and tips from their colleagues.The market launch of the Minnity app is planned for the end of 2018.
Digital Health
MyBasePair sells customized DNA-testsand for the Health, Fitness and Beauty industries.
EIT Health BeNe MyBasePair
Company name: MyBasePairAddress: Oxfordlaan 70,6229 EV Maastricht, the NetherlandsContact person: prof. Maurice Zeegers, PhDEmail: [email protected] number: +31 6 188 36 420 Website: www.mybasepair.com
MyBasePair (MBP) has developed a massive data-driven algorithm that can predict disease risks, sport abilities and skin ageing based on DNA and lifestyle assessmentse.g.1,2. It has subsequent-ly developed DNA test kits to be sold to healthcare, sports, wellness and cosmetics organizations. These professionals will resell under their own brand name. MBP takes care of all logistics, lab-analyses, analytics and advice report generation. Currently only a handful of companies offer DNA tests on the global market. MBP outperforms its competition by offering the deepest and most comprehensive profiling possible and by providing cues to action for life style change. MBPs large-scale market research3 has shown 5% willingness to buy. Market entry is expected to take place in 2018.
Digital Health
MyBasePairlive a longer, healthier and happier life
Precision in Neuropsychiatry
EIT Health InnoStars NeuroPsyAI
Company name: Neuropsyai - Serviços e InvestigaçãoEm Neurociências, LdaAddress: Praça Conde Agrolongo, Nº 123, Edificio Gnration 4700-034 Braga, PortugalContact person: Diana Prata, PhDEmail: [email protected]: +35 1966595936Website: www.neuropsycad.com
NeuroPsyAI uses artificial intelligence to identify disease ‘signatures’ of neurodegenerative illnesses in conventional brain scans. As currently 1/3 of cases of Alzheimer’s and Parkinson’s disease are mis-diagnosed, this software-as-a-service allows for the timely detection of the two most common neurodegenerative illnesses, for an earlier and more accurate diagnosis (>90%), by clinicians and pharma companies. As the right treatment can thus start earlier, disease progres-sion is slowed and healthcare is more cost-effective. With a served market of 1.3 Million new patients every year (US and EU), and a highly scalable technology, NeuroPsyAI promises to revolu-tionize mental healthcare.
Digital Health
Non-contact clinical grade home diagnosis of sleep apnea
EIT Health Germany Sleepiz
Company name: Sleepiz AGAddress: Häringstrasse 20, 8001 Zürich, Switzerland Contact person: Max SiegholdEmail: [email protected] number: +41-79 137 2557
Sleepiz AG is a Swiss start-up by graduates from ETH Zurich and St. Gallen (HSG), backed by lead-ing hospitals. 1 Billion people suffer from sleep apnea and more than 80% are undiagnosed! If untreated, it leads to heart failure, diabetes, accidents and productivity loss. The state of the art demands hospitalization, full-night supervision with 30+ cables. As a result, doctors are request-ing more efficient screening solutions without compromising reliability. Using wireless signals, our device measures vital signs without touching the patient - enabling non-contact home diag-nosis of sleep apnea. Coupled with machine learning and secure cloud sharing, we empower doc-tors to diagnose efficiently.
Digital Health
A virtual companion addressing fears and concernsof patients with chronic disease
EIT Health France WeFight
Company name: WeFightAddress: 18 RPT Benjamin Franklin,34000 Montpellier, FranceContact person: Pierre NectouxEmail: [email protected] Phone: +33 666374774Website: https://www.wefight.co/
Today patients with chronic disease see their doctors once every 3 months. Wefight’s ambition is to never leave these patients alone. Our team made my doctors, pharmacists and engineers developed Vik. Vik understands patients’ needs and answers it 24/7. In 9 month Vik reached 4000 patients with breast cancer in France, 25% are active every day. We have a direct access to patient and we engage them on the long term. Pharmaceuticals companies which are under pressure to perform phase 4 studies already pay us to grow our user base (3 clients). We signed a partnership with the worldwide leader of health data to reach a market of +260 M USD per year. We are look-ing for seed fundraising.
Digital Health
YAPILI. Delivering Health@Hand across Africa.
EIT Health BeNe Yapili
Company name: YAPILIAddress: Prinses Margrietplantsoen 33, 2595AMThe Hague, the NetherlandsContact person: Enya Seguin, CEO & Co-Founder Email: [email protected]: http://www.yapili.com
Access to Internet is growing much faster than access to healthcare in Africa. What if we could leverage mobile technology to enhance access to healthcare. What if health advice could be at hand? This is YAPILI. We connect African users to health professionals anywhere in the world. We empower people to own their health by enabling our users to store their medical information on YAPILI. YAPILI tackles various problems within the healthcare ecosystem in African countries. Around 30% of Africans have a smartphone. Internet penetration is also relatively high in some countries across the continent such as 70% in Kenya. People are actively using mobile technology to interact and enhance the effectiveness of tasks in their daily lives. Let’s deliver Health@Hand!
Digital Health
European Health Catapult Winners, EIT Health Summit in London, December 2017
Join us at the Semifinals and meet top notch European health startups!
eithealth.eu
/EITHealth
@EITHealth
/eithealth